Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Sagar Lonial, Brendan M Weiss, Saad Z Usmani...
https://pubmed.ncbi.nlm.nih.gov/26778538/Actively Recruiting
Led by Tata Memorial Centre · Updated on 2026-10-27
52
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating a modified, less frequent dosing schedule of daratumumab combined with standard VRd therapy bortezomib, lenalidomide, and dexamethasone for treating adults with newly diagnosed multiple myeloma. This phase 2, single-arm study aims to see if this approach increases the rate of minimal residual disease MRD negativity after four cycles of induction therapy, while also assessing safety, drug levels, and clinical response. Participants will receive four 28-day cycles of induction therapy including daratumumab given intravenously on days 1, 15, 29, 50, 71, and 92 weekly subcutaneous bortezomib oral lenalidomide daily for 21 days followed by a 7-day break and weekly dexamethasone. After induction, transplant-eligible patients may proceed to autologous stem cell transplant, while others continue VRd therapy for up to 9-12 cycles followed by maintenance treatment. During the study, participants will undergo bone marrow testing for MRD within two weeks after cycle 4, along with blood tests after cycles 2 and 4 to monitor treatment response. Researchers will also assess progression-free survival over two years, safety, pharmacokinetics of daratumumab, stem cell yield, and time to engraftment for transplant patients. Immune cell subsets will be explored as part of the research outcomes. The study duration is planned for four years.
CONDITIONS
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
D
Dr.Sumeet Mirgh, MBBS MD DM Clinical Hematology
D
Dr. Anant Gokarn, MBBS MD DM Medical Oncology
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tata Memorial Centre
Lead Sponsor
Indian Council of Medical Research
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 4 months
Participants receive four 28-day cycles of daratumumab combined with bortezomib, lenalidomide, and dexamethasone according to the study schedule.
Regular visits for treatment and monitoring during each cycle
Duration - Within 2 weeks after cycle 4 completion
Bone marrow testing and blood tests are performed to assess minimal residual disease and treatment response after induction therapy.
1 to 2 visits for assessments
Duration - Varies depending on transplant eligibility and treatment plan
Transplant-eligible participants may proceed to stem cell transplant, while others continue VRd treatment and maintenance as recommended by their doctors.
Visits as needed for transplant or continued therapy
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sagar Lonial, Brendan M Weiss, Saad Z Usmani...
https://pubmed.ncbi.nlm.nih.gov/26778538/Kyeongmin Kim, Mitch A Phelps
https://pubmed.ncbi.nlm.nih.gov/37129750/Meletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro...
https://pubmed.ncbi.nlm.nih.gov/34087126/Antonio Palumbo, Asher Chanan-Khan, Katja Weisel...
https://pubmed.ncbi.nlm.nih.gov/27557302/Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing...
https://pubmed.ncbi.nlm.nih.gov/27531679/Elias K Mai, Thomas Hielscher, Uta Bertsch...
https://pubmed.ncbi.nlm.nih.gov/38062124/Pieter Sonneveld, Meletios A Dimopoulos, Mario Boccadoro...
https://pubmed.ncbi.nlm.nih.gov/38084760/X S Xu, X Yan, T Puchalski...
https://pubmed.ncbi.nlm.nih.gov/27859027/Michel Attal, Valerie Lauwers-Cances, Cyrille Hulin...
https://pubmed.ncbi.nlm.nih.gov/28379796/Bruno Paiva, Noemi Puig, Maria-Teresa Cedena...
https://pubmed.ncbi.nlm.nih.gov/31770060/Tata Memorial Centre
Lead Sponsor
Indian Council of Medical Research
Collaborating Sponsor